{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+Control",
    "query": {
      "intervention": "Ranibizumab Control"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 50,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+Control&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T11:16:31.852Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00509795",
      "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1217,
      "start_date": "2007-08",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-12-28",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 176,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509795"
    },
    {
      "nct_id": "NCT01934556",
      "title": "A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.3 mg intravitreal injection",
          "type": "DRUG"
        },
        {
          "name": "Guided Laser Photocoagulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Palmetto Retina Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 150,
      "start_date": "2013-11",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • West Columbia, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934556"
    },
    {
      "nct_id": "NCT03211234",
      "title": "Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "2.0 mg DE-122 Injectable Solution + Lucentis",
          "type": "DRUG"
        },
        {
          "name": "4.0 mg DE-122 Injectable Solution + Lucentis",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2017-07-05",
      "completion_date": "2020-01-31",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03211234"
    },
    {
      "nct_id": "NCT03423823",
      "title": "Ziv-aflibercept Efficacy in Better Regulating AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Macular Degeneration",
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ziv-Aflibercept 25 MG/ML [Zaltrap]",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kapil Kapoor",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-07",
      "completion_date": "2020-06-26",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 1,
      "location_summary": "Virginia Beach, Virginia",
      "locations": [
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423823"
    },
    {
      "nct_id": "NCT02222610",
      "title": "Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Radiation Retinopathy"
      ],
      "interventions": [
        {
          "name": "0.5 mg ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Targeted Retinal Photocoagulation (TRP)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Greater Houston Retina Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2014-09-23",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 4,
      "location_summary": "Dallas, Texas • Houston, Texas • Katy, Texas + 1 more",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Katy",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222610"
    },
    {
      "nct_id": "NCT04690556",
      "title": "Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "LUBT010 (proposed ranibizumab biosimilar)",
          "type": "DRUG"
        },
        {
          "name": "Lucentis (ranibizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lupin Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2020-09-14",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Delray Beach, Florida • Hagerstown, Maryland + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04690556"
    },
    {
      "nct_id": "NCT00454389",
      "title": "A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Epi-Rad90™ Ophthalmic System",
          "type": "DEVICE"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NeoVista",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 494,
      "start_date": "2007-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2011-07-27",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454389"
    },
    {
      "nct_id": "NCT00766337",
      "title": "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Sirolimus in combination with ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo in combination with ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2008-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00766337"
    },
    {
      "nct_id": "NCT07007065",
      "title": "Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Surabgene Lomparvovec (ABBV-RGX-314)",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 561,
      "start_date": "2025-11-05",
      "completion_date": "2033-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 53,
      "location_summary": "Mesa, Arizona • Sun City, Arizona • Campbell, California + 49 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07007065"
    },
    {
      "nct_id": "NCT02140151",
      "title": "Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.5mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California Desert Retina Consultants, MC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2014-09-17",
      "completion_date": "2020-07-09",
      "has_results": false,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-09-02T11:16:31.852Z",
      "location_count": 4,
      "location_summary": "Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02140151"
    }
  ]
}